ondansetron has been researched along with Germinoblastoma in 12 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 9.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 9.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 9.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 9.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 9.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid." | 8.02 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. ( Kamiya, T; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Mori, T; Okayama, M; Sakurai, M; Tanigawa, T, 2021) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 7.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 6.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 5.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| "The aim of the present study was to compare the antiemetic efficacy of ondansetron (OND) with metoclopramide (MCP), both combined with corticosteroid (CS) in patients with malignant lymphoma." | 5.08 | Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. ( Jørgensen, M; Victor, MA, 1996) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 5.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 5.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "Anti-emetic effects, safety and usefulness of Ondansetron given intravenously at 4 mg once daily for consecutive 3-5 days were investigated against nausea and emesis induced by non-platinum anticancer drugs." | 5.07 | [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 5.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Although NK1RA is generally recommended for cisplatin-containing regimen, our results suggest that ondansetron effectively controlled emesis in patients receiving ESHAP therapy which includes high-dose corticosteroid." | 4.02 | Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma. ( Kamiya, T; Kato, J; Kikuchi, T; Koda, Y; Mizuno, K; Mori, T; Okayama, M; Sakurai, M; Tanigawa, T, 2021) |
| "A clinical study of palonosetron was performed to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC) before hematopoietic stem cell transplantation (HSCT) using a historical control group of patients treated with ondansetron as the comparative drug." | 3.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days." | 2.69 | Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 2.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kamiya, T | 1 |
| Sakurai, M | 1 |
| Kikuchi, T | 1 |
| Okayama, M | 1 |
| Mizuno, K | 1 |
| Tanigawa, T | 1 |
| Koda, Y | 1 |
| Kato, J | 1 |
| Mori, T | 1 |
| Rzepecki, P | 1 |
| Pielichowski, W | 1 |
| Oborska, S | 1 |
| Barzal, J | 1 |
| Mlot, B | 1 |
| Zeng, W | 1 |
| Zhou, J | 2 |
| Zhang, P | 1 |
| Jørgensen, M | 1 |
| Victor, MA | 1 |
| Coiffier, B | 1 |
| Khayat, D | 1 |
| Misset, JL | 1 |
| Votan, B | 1 |
| Xu, B | 1 |
| Zhou, A | 1 |
| Slabý, J | 1 |
| Trnený, M | 1 |
| Procházka, B | 1 |
| Klener, P | 1 |
| Kodama, F | 1 |
| Mohri, H | 1 |
| Motomura, S | 1 |
| Fukawa, H | 1 |
| Tanabe, J | 1 |
| Koharasawa, H | 1 |
| Kanamori, H | 1 |
| Hashimoto, Y | 1 |
| Harano, H | 1 |
| Sakai, R | 1 |
| Tomita, N | 1 |
| Fujimaki, K | 1 |
| Takemura, S | 1 |
| Hattori, M | 1 |
| Nukariya, N | 2 |
| Niitani, H | 3 |
| Taguchi, T | 3 |
| Furue, H | 3 |
| Ota, K | 3 |
| Tsukagoshi, S | 3 |
| Ariyoshi, Y | 3 |
| Ikeda, M | 3 |
| Akasaka, Y | 3 |
| Ohta, J | 3 |
| Suminaga, M | 1 |
| Cunningham, D | 1 |
| Hawthorn, J | 1 |
| Pople, A | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Challoner, T | 1 |
| Coombes, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ondansetron and Germinoblastoma
| Article | Year |
|---|---|
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
9 trials available for ondansetron and Germinoblastoma
| Article | Year |
|---|---|
[The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1995 |
Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemot | 1996 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2002 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
3 other studies available for ondansetron and Germinoblastoma
| Article | Year |
|---|---|
Efficacy of ondansetron against emesis induced by a multiple-day cisplatin-based chemotherapy regimen for malignant lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imidazoles; Injections, Intravenous; Lympho | 1987 |